Cite
Hill JA, Krantz EM, Hay KA, et al. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019;3(22):3590-3601doi: 10.1182/bloodadvances.2019000717.
Hill, J. A., Krantz, E. M., Hay, K. A., Dasgupta, S., Stevens-Ayers, T., Bender Ignacio, R. A., Bar, M., Maalouf, J., Cherian, S., Chen, X., Pepper, G., Riddell, S. R., Maloney, D. G., Boeckh, M. J., & Turtle, C. J. (2019). Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood advances, 3(22), 3590-3601. https://doi.org/10.1182/bloodadvances.2019000717
Hill, Joshua A, et al. "Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy." Blood advances vol. 3,22 (2019): 3590-3601. doi: https://doi.org/10.1182/bloodadvances.2019000717
Hill JA, Krantz EM, Hay KA, Dasgupta S, Stevens-Ayers T, Bender Ignacio RA, Bar M, Maalouf J, Cherian S, Chen X, Pepper G, Riddell SR, Maloney DG, Boeckh MJ, Turtle CJ. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019 Nov 26;3(22):3590-3601. doi: 10.1182/bloodadvances.2019000717. PMID: 31743392; PMCID: PMC6880890.
Copy
Download .nbib